Korro Bio Completes $116M Series B Financing To Expand The Frontier Of Genetic Medicine Through Its Pipeline Of Rna Editing Programs

Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the completion of a $116M Series B financing. This financing will enable Korro to advance its lead program in development for patients with Alpha-1 Antitrypsin Deficiency (AATD), an inherited genetic disorder leading to liver and lung disease, while expanding its pipeline to address prevalent diseases across multiple therapeutic areas.